

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT
UNAUDITED OPERATING STATISTICS FOR THE YEAR ENDED
DECEMBER 31, 2024

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company (the “**Shareholders**”) and potential investors with updated information in relation to the latest business and product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the year ended December 31, 2024, and the comparative figures as set out below.

	For the year ended December 31,		
	2024	2023	Change
	<i>RMB'million</i>	<i>RMB'million</i>	<i>%</i>
	Approximately		Approximately
Revenue	295.0–305.0	208.0	41.8–46.6

The increase in revenue was primarily attributable to the following reasons:

- (i) Following the Group’s acquisition of BMX Holdco Pte. Ltd., the Group leveraged its global sales network to achieve international sales of domestically developed products, driving the Group’s global sales revenue growth;

- (ii) In 2024, the Group successfully developed significant customer relationships. For example, in North America, the Group entered into a sale and purchase agreement with Gattaca Genomics LLC for Geri® Time-lapse Incubators, and in China, the Group entered into a strategic cooperation agreement with Shanghai Jinghua Medical Management Co., Ltd. (上海菁華醫療管理股份有限公司) for products including andrology testing, embryo culture, and cryopreservation, etc.; and
- (iii) In 2024, the Group obtained medical device registration certificates for its cryopreservation system — liquid nitrogen storage system (BSG800A and BSG800C), DA5000 high-throughput gene sequencer, and sperm quality analyzer (BKA210), further enriching the Group’s product pipeline and promoting the market penetration and sales growth of the Group’s products.

The information contained in this announcement is based solely on a preliminary assessment of the unaudited consolidated management accounts and relevant revenue estimates of the Group for the year ended December 31, 2024 made available to the Board as of the date of this announcement. This information has not been reviewed, confirmed or audited by the Company’s auditors nor reviewed by the audit committee of the Company, and the actual financial results of the Group for the year ended December 31, 2024 may be subject to adjustments. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the year ended December 31, 2024 which is expected to be published in March 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, January 13, 2025

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. YANG Ying as executive Directors; Mr. WANG Weipeng and Mr. LING Yang as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.